Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

[1]  B. Wang,et al.  Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review , 2016, PloS one.

[2]  A. Bezjak,et al.  CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). , 2016 .

[3]  R. Bremnes,et al.  Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer , 2016, Acta oncologica.

[4]  Ying Cheng,et al.  Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer , 2016, BMC Cancer.

[5]  Kendra Johnson,et al.  Integration of and adherence to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) in a Community Cancer Center , 2015 .

[6]  G. Giaccone,et al.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Lee,et al.  Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limited stage small cell lung cancer , 2015, Radiation oncology journal.

[8]  D. de Ruysscher,et al.  Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Jett,et al.  Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[10]  K. Kiura,et al.  Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. , 2012, Lung cancer.

[11]  J. Virchow,et al.  Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  R. Herbst,et al.  Small-cell lung cancer: prognostic factors and changing treatment over 15 years. , 2012, Clinical lung cancer.

[13]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[14]  Xuwei Cai,et al.  The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer , 2011, Radiation oncology.

[15]  P. Lambin,et al.  Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  C. Faivre-Finn,et al.  167 CONVERT: Concurrent ONce-daily VErsus twice-daily RadioTherapy. A phase III randomised controlled trial for patients with limited stage small cell lung cancer (LS-SCLC) and good performance status , 2009 .

[17]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[18]  P. Lambin,et al.  Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. , 2007, Cancer treatment reviews.

[19]  T. Björk-Eriksson,et al.  Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998–2004. , 2007, Acta oncologica.

[20]  P. Lambin,et al.  Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Socinski,et al.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Gulliford,et al.  Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services? , 2003, British Journal of Cancer.

[23]  R. Hatlevoll,et al.  The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. , 2001, Lung cancer.

[24]  R. Hatlevoll,et al.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[27]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[28]  R. A. Green,et al.  Alkylating agents in bronchogenic carcinoma. , 1969, The American journal of medicine.